Hard Topics — Compounders, Supply Shortages, and the MFN Pricing Deal

Lilly's success story has hard edges. The 2024 Mounjaro/Zepbound supply shortage left patients without medicines. Lilly is in active legal battles with compounding pharmacies. The Trump-administration "Most Favored Nation" pricing deal in September 2025 cut prices 85% for Medicaid/Medicare. None of this gets discussed in glossy investor presentations, but a smart interviewer may probe how you think about these topics — because integrity, ethics, and access are central to Lilly's identity. This module gives you balanced, factual framings so you can engage maturely without overcommitting to a partisan view.